Abstract:Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of pathological cardiac hypertrophy can effectively reduce the occurrence of heart failure. Abundant factors, such as adrenergic, angiotensin, and endothelin (ET-1) receptors, have been shown to participate in the regulation of pathological cardiac hypertrophy. Recently, an increasing number of studies have indicated that circRNA and circRNA-miRNA–mRNA network regulation is indispensable for the posttranscriptional regulation of mRNA in cardiac hypertrophy. In our study, the morphological, cardiac function and pathological changes during cardiac hypertrophy were investigated. RNA sequencing identified 93 circRNAs that were differentially expressed in the TAC_2w group, and 55 circRNAs in the TAC_4w group compared with the sham group. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses identified several significant pathways, including hypertrophic cardiomyopathy, extracellular matrix (ECM)-receptor interaction and focal adhesion. Coexpression analyses were performed for differentially expressed circRNAs and differentially expressed mRNAs. Based on gene set enrichment analysis (GSEA), 8 circRNAs (mmu-Nfkb1_0001, mmu-Smad4_0007, mmu-Hecw2_0009, mmu-Itgbl1_0002, mmu-Lrrc2_0005, mmu-Cpeb3_0007, mmu-Ryr2_0040, and mmu-Rtn4_0001) involved in cardiac hypertrophy and cardiac fibrosis were identified. We validated some key circRNAs by qPCR. The crucial coexpression of circRNA–mRNA and its interaction with miRNA showed the possible mechanism of circRNAs in the process of cardiac dysfunction. Our results may provide promising targets for the treatment of pathological cardiac hypertrophy and fibrosis.

Non-coding RNAs in cardiac ﬁbrosis: emerging biomarkers and therapeutic targets.

Noncoding RNAs and Cardiac Fibrosis

Epigenetic signatures in cardiac fibrosis: Focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity

Emerging Roles Of Long Non-Coding Rnas In Renal Fibrosis

TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus

The Function and Therapeutic Potential of lncRNAs in Cardiac Fibrosis

Mechanism of action of non-coding RNAs and traditional Chinese medicine in myocardial fibrosis: Focus on the TGF-β/Smad signaling pathway

Non-coding RNAs in Physiological Cardiac Hypertrophy

Noncoding RNA network crosstalk in organ fibrosis

Non-coding RNAs: targets for Chinese herbal medicine in treating myocardial fibrosis

The regulation of circRNA and lncRNA protein binding in cardiovascular diseases: Emerging therapeutic targets

Long Noncoding RNA: a New Contributor and Potential Therapeutic Target in Fibrosis

Long Non-coding RNA: An Emerging Contributor and Potential Therapeutic Target in Renal Fibrosis

Non-coding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential

Expression Signature of Lncrnas and Their Potential Roles in Cardiac Fibrosis of Post-Infarct Mice

Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease

Role of noncoding RNAs in liver fibrosis

Non‐coding RNAs in Cardiomyocyte Proliferation and Cardiac Regeneration: Dissecting Their Therapeutic Values

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction

Pathological Bases and Clinical Application of Long Noncoding RNAs in Cardiovascular Diseases